Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Cindy Delbrook"'
Autor:
Brandon M. Wiley, Amita Kulshreshtha, Bonnie Yates, Daniel W. Lee, Stanislav Sidenko, Haneen Shalabi, Julia W. Cohen, Nirali N. Shah, Cindy Delbrook, Crystal L. Mackall, Vandana Sachdev, Doug R Rosing
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundChimeric antigen receptor (CAR) T-cell-associated cytokine release syndrome (CRS) may present with tachycardia, hemodynamic instability and reduced cardiac function. Pediatric CAR studies examining cardiac toxicity are limited.MethodsWe rep
Autor:
Staci Martin, Robbie G. Majzner, Constance M. Yuan, Bonnie Yates, Jack F. Shern, Haneen Shalabi, Haiying Qin, David F. Stroncek, Marianna Sabatino, Terry J. Fry, Boro Dropulic, Cindy Delbrook, Yang Feng, Nirali N. Shah, Thomas J. Fountaine, Rimas J. Orentas, Daniel W. Lee, Crystal L. Mackall, Maryalice Stetler-Stevenson, Sneha Ramakrishna, Pamela L. Wolters, Dimiter S. Dimitrov, Ling Zhang, Sang M. Nguyen
Publikováno v:
Nature Medicine. 24:20-28
Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent effects in relapsed and/or refractory pre-B cell acute lymphoblastic leukemia (B-ALL), but antigen loss is a frequent cause of resistance to CD19-targeted immunotherapy. CD22 is al
Autor:
Eli Kane, Marie Claire Roderick, Staci Martin, Daniel W. Lee, Nirali N. Shah, Kari Struemph, Cindy Delbrook, Terry J. Fry, Crystal L. Mackall, Pamela L. Wolters, Haneen Shalabi, Mary Anne Toledo-Tamula, Bonnie Yates
Neurotoxicity associated with CAR-T cell therapy can be life-threatening. With rapid development of CAR-T therapies, a systematic method is needed to identify and monitor symptoms of neurotoxicity, elucidate potential etiologies, and compare toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ddd097f65f1a686bb2854d871ecc08c
https://europepmc.org/articles/PMC6086728/
https://europepmc.org/articles/PMC6086728/
Autor:
Jedd D. Wolchok, Maya Lodish, Matthew Wright, Crystal L. Mackall, Donna Bernstein, Carlos Rodriguez-Galindo, Cindy Delbrook, Melinda S. Merchant, Leonard H. Wexler, Howard Streicher, Kristin Baird, Rachel Bishop
Publikováno v:
Clinical Cancer Research. 22:1364-1370
Purpose: Ipilimumab is a first-in-class immune checkpoint inhibitor approved for treatment of metastatic melanoma but not studied in children until this phase I protocol. Experimental Design: This study examined safety, pharmacokinetics, and immunoge
Autor:
Jack F. Shern, Elaine S. Jaffe, Ira Lignugaris Kraft, Haneen Shalabi, Constance M. Yuan, Terry J. Fry, Hao-Wei Wang, Julie D. Zimbelman, Daniel W. Lee, Maryalice Stetler-Stevenson, Roger Giller, Cindy Delbrook, Nirali N. Shah, Bonnie Yates
Diffuse large B-cell lymphoma (DLBCL) is the predominant subtype of Non-Hodgkin lymphoma (NHL) in adolescents and adults. Originating from a B-cell lineage, the neoplastic cells typically express pan-B- cell antigens including CD19, CD20 and CD22.[1]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca52ca71feff65eb6d3144942af93cda
https://europepmc.org/articles/PMC5927974/
https://europepmc.org/articles/PMC5927974/
Autor:
Crystal L. Mackall, Tolu Ariyo, Nirali N. Shah, David F. Stroncek, Terry J. Fry, Alan S. Wayne, Cindy Delbrook, David M. Loeb, Hahn Khuu, Mark Raffeld
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 22(12)
Relapse of hematologic malignancies is the primary cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HCT). Treatment for post-HCT relapse using donor lymphocyte infusion (DLI) has limited utility, particularly in th